111 related articles for article (PubMed ID: 30516664)
1. Small Primary Cutaneous γδT-Cell Lymphoma Lesions Successfully Treated With Pralatrexate.
Imataki O; Uchida S; Yokokura S; Uemura M; Kadowaki N
Clin Nucl Med; 2019 Feb; 44(2):e85-e86. PubMed ID: 30516664
[TBL] [Abstract][Full Text] [Related]
2. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.
Foss FM; Parker TL; Girardi M; Li A
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e445-e447. PubMed ID: 30181105
[No Abstract] [Full Text] [Related]
3. Clinical remission of primary aggressive CD8+ cutaneous T-cell lymphoma after pralatrexate infusion.
Kerdel FA; Styperek AR; Maini A
JAMA Dermatol; 2014 Mar; 150(3):320-2. PubMed ID: 24452280
[No Abstract] [Full Text] [Related]
4. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
5. F-18 FDG PET/CT in granulomatous slack skin.
Hua F; Guan Y; Dai W; Zhao J; Feng X
Clin Nucl Med; 2010 Feb; 35(2):95-7. PubMed ID: 20090455
[No Abstract] [Full Text] [Related]
6. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma.
Kuo PH; McClennan BL; Carlson K; Wilson LD; Edelson RL; Heald PW; Girardi M
Mol Imaging Biol; 2008; 10(2):74-81. PubMed ID: 18196347
[TBL] [Abstract][Full Text] [Related]
7. Extensive Cutaneous-Mucosal and Muscular Involvement of Gamma/Delta Cutaneous T-Cell Lymphoma on 18 F-FDG PET/CT.
Peslier H; Reichart J; Boursot C; Cohen-Tannugi K; Lacoeuille F
Clin Nucl Med; 2024 May; 49(5):e206-e207. PubMed ID: 38389221
[TBL] [Abstract][Full Text] [Related]
8. The utility of positron emission tomography with and without computed tomography in patients with nonmelanoma skin cancer.
Duncan JR; Carr D; Kaffenberger BH
J Am Acad Dermatol; 2016 Jul; 75(1):186-96. PubMed ID: 26992283
[TBL] [Abstract][Full Text] [Related]
9. Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas.
Shapiro M; Yun M; Junkins-Hopkins JM; Vittorio CC; Schulman N; Saidman BH; Fried RG; Rook AH; Alavi A
J Am Acad Dermatol; 2002 Oct; 47(4):623-8. PubMed ID: 12271315
[TBL] [Abstract][Full Text] [Related]
10. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
Horwitz SM; Kim YH; Foss F; Zain JM; Myskowski PL; Lechowicz MJ; Fisher DC; Shustov AR; Bartlett NL; Delioukina ML; Koutsoukos T; Saunders ME; O'Connor OA; Duvic M
Blood; 2012 May; 119(18):4115-22. PubMed ID: 22394596
[TBL] [Abstract][Full Text] [Related]
11. Colonic adenomas detected by F-FDG PET.
Felig DM; Sedarat A; Agress H; Waintraub SE
Gastrointest Endosc; 2002 Nov; 56(5):734. PubMed ID: 12397286
[No Abstract] [Full Text] [Related]
12. Additional Findings of 18 F-AIF-FAPI-42 PET/CT in a Patient With Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma : Comparisons With 18 F-FDG PET/CT.
Liu G; Li Y; Du B; Cui Y; Li X
Clin Nucl Med; 2024 May; 49(5):e199-e201. PubMed ID: 38465934
[TBL] [Abstract][Full Text] [Related]
13. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate.
Leitenberger JJ; Berthelot CN; Polder KD; Pro B; McLaughlin P; Jones D; Duvic M
J Am Acad Dermatol; 2008 Mar; 58(3):480-4. PubMed ID: 18280345
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate and Pralatrexate.
Wood GS; Wu J
Dermatol Clin; 2015 Oct; 33(4):747-55. PubMed ID: 26433846
[TBL] [Abstract][Full Text] [Related]
15. Before and after treatment 18F-FDG PET/CT images in a patient with cutaneous T-cell lymphoma.
Kim JS; Jeong YJ; Sohn MH; Lim ST; Kim DW; Jeong HJ; Kwak JY; Yim CY
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1995. PubMed ID: 20658231
[No Abstract] [Full Text] [Related]
16. Primary Cutaneous Natural Killer/T-Cell Lymphoma: A Posttransplant Lymphoproliferative Disorder Demonstrated by 18F-FDG PET/CT.
Lu X; Kan Y; Wang W; Yang J
Clin Nucl Med; 2021 Jul; 46(7):595-598. PubMed ID: 33512953
[TBL] [Abstract][Full Text] [Related]
17.
Ram-Wolff C; Vercellino L; Brice P; La Selva R; Bagot M
Eur J Dermatol; 2017 Oct; 27(5):496-504. PubMed ID: 28721937
[TBL] [Abstract][Full Text] [Related]
18. 18FDG PET/CT in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.
Dejust S; Morland D; Durot E; Grange F; Papathanassiou D
Clin Nucl Med; 2020 May; 45(5):403-404. PubMed ID: 32209875
[TBL] [Abstract][Full Text] [Related]
19. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate.
Foss FM; Parker TL; Girardi M; Li A
Leuk Lymphoma; 2019 Dec; 60(12):2927-2930. PubMed ID: 31119966
[TBL] [Abstract][Full Text] [Related]
20. Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas.
Spaccarelli N; Gharavi M; Saboury B; Cheng G; Rook AH; Alavi A
Hell J Nucl Med; 2014; 17(2):78-84. PubMed ID: 24997076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
